UNITED STATES
SECURITIES AND EXCHANGE COMMISSON
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
TARO PHARMACEUTICAL INDUSTRIES LTD.
(Exact name of registrant as specified in its charter)
|
Israel
|
|
98-0358412
|
|
(Jurisdiction of Incorporation or Organization)
|
|
(I.R.S. Employer Identification No.)
|
14 Hakitor Street, Haifa Bay 26110, Israel
(Address of Principal Executive Offices)
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. [X]
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A. (d), check the following box. [ ]
Securities Act registration statement file number to which this form relates: (if applicable)
Securities to be registered’ pursuant to Section 12(b) of the Act:
|
Title of each class to be registered
|
Name of each exchange on which each class is to be registered
|
| |
|
|
Ordinary Shares, NIS 0.0001 nominal value per share
|
New York Stock Exchange, Inc.
|
Securities to be registered pursuant to Section 12 (g) of the Act:
None
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. Description of Registrant’s Securities to be Registered.
The description of the ordinary shares, NIS 0.0001 nominal par value per share, of Taro Pharmaceutical Industries Ltd. (the “Registrant”), as set forth under the caption “Voting, Rights Attached to Shares, Shareholders’ Meetings and Resolutions” in Item 10.B of the Registrant’s Annual Report for the year ended December 31, 2010 on Form 20-F, as originally filed with the Securities and Exchange Commission (the “Commission”) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 on June 29, 2011 (Registration No. 000-22286), including exhibits, as amended on January 10, 2012 and as may be subsequently amended from time to time, is hereby incorporated by reference.
Item 2. Exhibits.
Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on the New York Stock Exchange and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities and Exchange Act of 1934.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
Date: March 19, 2012
TARO PHARMACEUTICAL INDUSTRIES LTD.
| By: |
/s/ James Kedrowski
|
|
| |
Name: |
James Kedrowski
|
|
| |
Title: |
Interim Chief Executive Officer and Director
|